Akynzeo Injection
Product Images NDC 69639-105

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Akynzeo (NDC 69639-105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Helsinn Therapeutics (u.s.), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Netupitant Chemical Structure (Akynzeo 1)

Chemical structure diagram depicting the molecular composition of the active ingredient in AKYNZEO. The diagram shows carbon, nitrogen, oxygen, and fluorine atoms arranged in a complex structure, characteristic of the drug's active molecule.*

FDA Label Image

Palonosetron Hydrochloride Chemical Structure (Akynzeo 2)

Chemical structure diagram of the active ingredient in AKYNZEO, showing a complex fused ring system with nitrogen atoms and a hydrochloride (HCl) component, corresponding to the medication from Helsinn Therapeutics (U.S.), Inc.*

FDA Label Image

Fosnetupitant Chem Structure (Akynzeo 2b)

Chemical structure of the active ingredient in AKYNZEO, showing a complex molecule with multiple rings, halogens, and functional groups consistent with pharmaceutical compounds.*

FDA Label Image

Image Description (Akynzeo Fig)

A bar chart titled 'Complete Response' comparing the efficacy of AKYNZEO versus Palonosetron over treatment cycles 2 to 6. Black bars represent AKYNZEO and white bars represent Palonosetron, showing higher complete response percentages for AKYNZEO in each cycle. Below the chart, sample sizes for each group and confidence intervals for the difference between groups are displayed.*

FDA Label Image

Pi-im1 (Akynzeo 4)

AKYNZEO capsules, 300 mg/0.5 mg, packaging label showing the product name and active ingredients netupitant and palonosetron. The label indicates each capsule contains 300 mg netupitant and 0.56 mg palonosetron hydrochloride equivalent to 0.50 mg palonosetron free base. It is distributed by Helsinn Therapeutics (U.S.), Inc. and manufactured by Helsinn Birex Pharmaceuticals Ltd., Dublin, Ireland. The package also includes the NDC 69639-101-01 and directions to push the blister to open.*

FDA Label Image

Image Description (Akynzeo 5)

AKYNZEO capsules, 300 mg netupitant and 0.5 mg palonosetron, box showing label with dosage and active ingredients. The packaging is held between fingers, displaying the Helsinn Therapeutics (U.S.), Inc. labeler name and NDC 69639-101-01. The label specifies prescription use and the capsule count as 1 capsule.*

FDA Label Image

Image Description (Akynzeo 6)

AKYNZEO capsules, 300 mg/0.5 mg, packaging label showing a single capsule package. The label lists netupitant and palonosetron as active ingredients with doses of 300 mg and 0.5 mg respectively. The labeler is Helsinn Therapeutics (U.S.), Inc., and the packaging indicates prescription-only use with a visible NDC number.*

FDA Label Image

Image Description (Akynzeo 7)

Box of Akynzeo capsules containing netupitant and palonosetron, dosage strength 300 mg/0.5 mg. The packaging shows capsules inside a blister strip and lists Helsinn Therapeutics (U.S.), Inc. as the labeler. The box features the Akynzeo brand prominently along with the active ingredients and strengths.*

FDA Label Image

Ndc 62856-796-01 Akynzeo (netupitant And Palonosetron) Capsules, 300mg/0.5mg (Akynzeo 8)

Packaging label for Akynzeo capsules containing netupitant 300mg and palonosetron 0.5mg. The label shows the product name, active ingredients with strengths, storage instructions at 20°C to 25°C with permitted excursions, and distribution details from Helsinn Therapeutics (U.S.), Inc. It also includes the NDC 69639-101-01, barcode, and notes that the product is Rx only.*

FDA Label Image

Ndc 62856-796-01 Akynzeo (netupitant And Palonosetron) Capsules, 300mg/0.5mg (Akynzeo 9)

Packaging label for Akynzeo capsules containing netupitant and palonosetron, 300 mg/0.5 mg strength. The label shows the product name, active ingredients, dosage form as capsules, and strength. It includes barcodes and manufacturer information for Helsinn Therapeutics (U.S.), Inc.*

FDA Label Image

Ndc 62856-796-04 Akynzeo (netupitant And Palonosetron) Capsules, 300mg/0.5mg (Akynzeo 11)

Label for Akynzeo capsules, containing netupitant and palonosetron, with a strength of 300 mg/0.5 mg per capsule. The label indicates it is for hospital use only, with a package size of 4 capsules. Manufactured by Helsinn Therapeutics (U.S.), Inc., the label includes storage instructions and regulatory information including the NDC 69639-101-04.*

FDA Label Image

Ndc 62856-796-04 Akynzeo (netupitant And Palonosetron) Capsules, 300mg/0.5mg (Akynzeo 10)

Label for Akynzeo capsules containing netupitant and palonosetron, 300 mg/0.5 mg per capsule. The label includes the NDC 69639-101-04 and lists Helsinn Birex Pharmaceuticals Ltd., Dublin, Ireland as the manufacturer, and Helsinn Therapeutics (U.S.), Inc., Iselin, NJ as the distributor. The capsule form and Rx only designation are visible.*

FDA Label Image

Akynzeo Vial Carton (Akynzeo 12)

AKYNZEO 235 mg/0.25 mg per vial for injection containing fosnetupitant and palonosetron. The label indicates the need for reconstitution and dilution before intravenous infusion, storage requirements at 2°C-8°C, and directs users to see package inserts for dosing. Distributed by Helsinn Therapeutics (U.S.), Inc., the label provides detailed ingredient information and warnings against certain diluents.*

FDA Label Image

Akynzeo Vial Label (Akynzeo 13)

Label for AKYNZEO for injection, containing fosnetupitant 235 mg and palonosetron 0.25 mg per vial. The single-dose vial requires reconstitution and dilution for intravenous infusion. Instructions include refrigerated storage at 2°C-8°C and protection from light. Distributed by Helsinn Therapeutics (U.S.), Inc.*

FDA Label Image

Akynzeo Vial Label (Vial Inj)

Label for Akynzeo injection, a single-dose vial containing 235 mg/0.25 mg per 20 mL of fosnetupitant and palonosetron. The label states storage instructions, dilution requirement for intravenous infusion, and lists the equivalent amounts of fosnetupitant chloride hydrochloride (260 mg) and palonosetron hydrochloride (0.28 mg). Distributed by Helsinn Therapeutics (U.S.), Inc.*

FDA Label Image

Akynzeo Vial Label (Carton Inj)

Packaging label for Akynzeo injection containing fosnetupitant and palonosetron. The strength is 235 mg/0.25 mg per 20 mL in a single dose vial. The label states the product must be diluted for intravenous infusion only. The labeler is Helsinn Therapeutics (U.S.), Inc., with manufacturing by Baxter Oncology GmbH, Germany. Additional storage and usage instructions are provided along with inactive ingredient details.*

FDA Label Image

Label (Ndc69639 106 01 Label)

Label of Akynzeo injection, 235 mg/0.25 mg per 20 mL (11.75 mg/0.0125 mg per mL), a single-dose vial for intravenous infusion. It contains fosnetupitant and palonosetron, with no need for further dilution. Distributed by Helsinn Therapeutics (U.S.), Inc., the label includes storage instructions and dosage references, along with a barcode and lot/expiration placeholders.*

FDA Label Image

Carton (Ndc69639 106 01 Carton)

Label for Akynzeo injection, fosnetupitant and palonosetron, 235 mg/0.25 mg per 20 mL (11.75 mg/0.0125 mg per mL), sterile solution for intravenous infusion. The label states it is a ready-to-use formulation requiring no further dilution. Manufactured by Baxter Oncology GmbH, distributed by Helsinn Therapeutics (U.S.), Inc. Instructions on storage and cautious use with divalent cations-containing solutions are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.